Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge in Participants With Chronic Kidney Disease Treated for Hyperkalaemia

NCT05347693 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05347693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05347693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge in Participants With Chronic Kidney Disease Treated for Hyperkalaemia
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
March 24, 2022
Completion date
December 10, 2024
Enrollment
186 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperkalaemia